Esomeprazole Magnesium
Product Images NDC 68071-2782

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 68071-2782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2782 4)

Label for Esomeprazole Magnesium 40mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label shows product NDC 68071-2782-4, contains #14 capsules. Capsules are white, oblong, opaque, with 'H' on the cap and 'E3' on the body. Packaged by Hetero Labs Limited in India. Storage recommended at 68-77°F. Rx only.*

FDA Label Image

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)

Chemical structure of esomeprazole magnesium showing the molecular arrangement including magnesium ion complexed with water molecules. The structure features two esomeprazole molecules coordinated to a magnesium ion.*

FDA Label Image

Esmoprazolemagnesiumfigure2 (Esomeprazolemagnesiumfigure2)

A line graph showing the percentage maintained over a span of 6 months for four groups: Esomeprazole Magnesium Delayed-Release Capsules 40 mg (N=82), 20 mg (N=86), 10 mg (N=61), and a placebo (N=43). The y-axis represents percent maintained from 0 to 100, and the x-axis represents time in months from 0 to 6, illustrating a decline over time, with higher doses maintaining a higher percentage.*

FDA Label Image

Esmoprazolemagnesiumfigure3 (Esomeprazolemagnesiumfigure3)

A line graph depicting percent maintained over a six-month period for four groups: Esomeprazole Magnesium Delayed-Release Capsules at 40 mg and 20 mg, Esomeprazole Magnesium Delayed-Release Capsules at 10 mg, and Placebo. The x-axis represents months and the y-axis shows percent maintained, illustrating comparative trends among these groups over time.*

FDA Label Image

Esomeprazolemagnesiumfigure4 (Esomeprazolemagnesiumfigure4)

A line graph depicting the percent of patients symptom-free over a 28-day diary period for Esomeprazole Magnesium Delayed-Release Capsules at 20 mg and 40 mg doses, compared to placebo. The vertical axis shows percent symptom-free, and the horizontal axis shows diary days from 0 to 28, with all groups trending upward over time.*

FDA Label Image

Esomeprazolemagnesiumfigure5 (Esomeprazolemagnesiumfigure5)

A line graph showing the percent of patients symptom-free over 28 diary days comparing Esomeprazole Magnesium Delayed-Release Capsules 40 mg, Esomeprazole Magnesium Delayed-Release Capsules 20 mg, and placebo. The vertical axis represents percent symptom-free patients, and the horizontal axis shows diary days from 0 to 28.*

FDA Label Image

Camber (Camber)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.